Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAON CL-10 vs MICRO-K LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving diuretics or other drugs that deplete potassium
Hypokalemia prevention or treatment,Diuretic-induced hypokalemia,Digitalis intoxication
Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.
10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.
Terminal elimination half-life is approximately 3-5 hours in healthy adults, reflecting rapid equilibration with the total body potassium pool. Clinically, the half-life is not directly applicable due to extensive intracellular distribution; steady-state is achieved within 24-48 hours.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Potassium is primarily excreted unchanged by the kidneys; metabolism is not significant.
Not metabolized; excreted primarily via kidneys.
Primarily renal elimination (>90% as unchanged drug); minor biliary/fecal excretion (<5%). Excretion is via glomerular filtration and tubular reabsorption; potassium excretion is influenced by aldosterone and acid-base status.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
Potassium is not significantly protein-bound; <5% bound to plasma proteins.
None (K+ is free ion).
Approximately 0.5 L/kg, representing distribution primarily into intracellular fluid (98% of total body potassium is intracellular). Clinical meaning: Low Vd indicates limited distribution to extracellular space; high intracellular uptake requires careful dosing to avoid hyperkalemia.
0.35 L/kg (approximate total body water; distributes primarily in extracellular fluid).
Oral: >90% absorbed via passive diffusion along the gastrointestinal tract. Intravenous: 100% bioavailability.
Oral: ~80-100% for microencapsulated KCl (MICRO-K), but can be incomplete due to slower release.
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
GFR 50-90 m L/min: no adjustment. GFR 30-49 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or reduce dose by 50-75% with close monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: avoid use or reduce dose by 50%.
Oral: 1-3 m Eq/kg/day in divided doses, maximum 3 m Eq/kg/day; not recommended for children <1 year.
1-3 m Eq/kg/day orally in 2-4 divided doses; maximum 1 m Eq/kg per dose and 100 m Eq/day.
Start at lowest dose (10 m Eq twice daily); monitor renal function and potassium levels; avoid doses exceeding 40 m Eq/day.
Initiate at lower end of dosing range (10-20 m Eq/day); monitor renal function and serum potassium frequently; adjust based on renal function.
Warning: Potassium chloride can cause hyperkalemia and cardiac arrest if given too rapidly or in excessive doses. Avoid in patients with severe renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics.
No black box warning.
Monitor serum potassium levels and renal function; avoid high doses or rapid infusion; use with caution in patients with cardiac disease or receiving digitalis; gastrointestinal irritation may occur with oral preparations.
Risk of hyperkalemia especially in renal impairment,Use with caution in cardiac disease,GI irritation or ulceration with oral forms,Slow release formulations may cause GI lesions
Severe renal impairment (e.g., anuria, oliguria), untreated Addison's disease, hyperkalemia from any cause, acute dehydration, heat cramps, concurrent use of potassium-sparing diuretics (e.g., amiloride, spironolactone), hypersensitivity to potassium chloride.
Hyperkalemia,Severe renal impairment,Untreated Addison's disease,Acute dehydration,Use of potassium-sparing diuretics
Avoid salt substitutes and low-sodium products that contain potassium chloride. No specific food restrictions beyond ensuring adequate water intake with each dose to prevent esophageal or gastric irritation.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, dried fruits, salt substitutes containing potassium chloride). Do not take with alcohol as it may increase GI irritation. Grapefruit juice has no significant interaction, but large amounts of any food high in potassium should be avoided.
Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been reported. Hypokalemia itself may pose maternal and fetal risks, but the drug does not have intrinsic teratogenic potential.
MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.
Potassium chloride is a normal constituent of breast milk. M/P ratio not applicable as potassium is present endogenously. Supplementation to correct maternal hypokalemia is considered safe during breastfeeding, as potassium levels in milk are tightly regulated and maternal supplementation does not significantly alter infant potassium levels.
Potassium is a normal component of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: not applicable (endogenous electrolyte).
No dose adjustment required for pregnancy. Maternal potassium requirements may increase slightly due to increased plasma volume and renal blood flow, but hypokalemia should be corrected per standard guidelines. Monitor serum potassium to avoid hyperkalemia.
No dose adjustment typically required. Maintain serum potassium within normal range. Monitor for hypokalemia or hyperkalemia as clinically indicated.
Kaon CL-10 is a solid oral dosage form of potassium chloride (KCl) 10 m Eq. Do not split or crush tablets; they must be swallowed whole with a full glass of water to reduce GI irritation. Monitor serum potassium, renal function, and ECG. Use with caution in patients with impaired renal function or those on ACE inhibitors, ARBs, or potassium-sparing diuretics. Rapid IV correction is reserved for severe hypokalemia with ECG changes.
MICRO-K LS contains potassium chloride microencapsulated granules for sustained release. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min), untreated Addison's disease, or hyperkalemia. Use with caution in patients with cardiac disease or concurrent use of ACE inhibitors, ARBs, or potassium-sparing diuretics. Do not crush or chew capsules; administer with a full glass of water to prevent GI mucosal damage. Monitor serum potassium regularly, especially in elderly and diabetic patients.
Take this medication with food and a full glass of water to prevent stomach upset.,Do not crush, chew, or split the tablet; swallow it whole.,Missing a dose: take it as soon as you remember unless almost time for the next dose; do not double up.,Report symptoms of high potassium: muscle weakness, tiredness, numbness/tingling, irregular heartbeat, or confusion.,Do not use salt substitutes or potassium-containing supplements unless directed by your doctor.
Take this medication exactly as prescribed, preferably with meals or a full glass of water.,Do not crush, chew, or break the capsules; swallow them whole.,Avoid foods high in potassium (e.g., bananas, oranges, tomatoes, salt substitutes) unless directed by your doctor.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, numbness/tingling, or dark/tarry stools.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAON CL-10 vs MICRO-K LS, answered by our medical review team.
KAON CL-10 is a Electrolyte Supplement (Potassium) that works by Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.. MICRO-K LS is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAON CL-10 and MICRO-K LS depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAON CL-10 is: Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.. The standard adult dose of MICRO-K LS is: 10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAON CL-10 and MICRO-K LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAON CL-10 is classified as Category C. Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been report. MICRO-K LS is classified as Category C. MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.